Effects of Aspirin on Intra-Platelet Vascular Endothelial Growth Factor, Angiopoietin-1, and P-Selectin Levels in Hypertensive Patients

American Journal of Hypertension

Volumn 19, Issue 9, 2006, Pages 970-977

  Nadar, Sunil ^a   Blann, Andrew D ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

angiopoeitin 1; aspirin; Hypertension; P selectin; platelets; vascular endothelial growth factor

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOPOIETIN 1; ANTILIPEMIC AGENT; PADGEM PROTEIN; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MALE; MEDICAL RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STOMACH DISEASE; THROMBOCYTE ACTIVATION; THROMBOCYTE STRUCTURE; THROMBOCYTE VOLUME; VASCULAR DISEASE;

AGED; ANGIOPOIETIN-1; ASPIRIN; BIOLOGICAL MARKERS; BLOOD PLATELETS; BLOOD PRESSURE; CASE-CONTROL STUDIES; CYCLOOXYGENASE INHIBITORS; ENGLAND; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33846238204     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2006.03.001     Document Type: Article

References (49)

1. Nadar S., and Lip G.Y. The prothrombotic state in hypertension and the effects of antihypertensive treatment. Curr Pharm Des 9 (2003) 1715-1732
2. Lip G.Y. Hypertension, platelets, and the endothelium. the "thrombotic paradox" of hypertension (or "Birmingham paradox") revisited. Hypertension 41 (2003) 199-200
3. Antithrombotic Trialist Collaboration. Collaborative meta analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. Br Med J 324 (2002) 71-86
4. Rao G.H. Physiology of blood platelet activation. Indian J Physiol Pharmacol 37 (1993) 263-275
5. Luscher T.F. Platelet-vessel wall interaction. role of nitric oxide, prostaglandins and endothelins. Baillieres Clin Haematol 6 (1993) 609-627
6. Colman R.W. Receptors that activate platelets. Proc Soc Exp Biol Med 197 (1991) 242-248
7. Minuz P., Patrignani P., Gaino S., Degan M., Menapace L., Tommasoli R., et al. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation 106 (2002) 2800-2805
8. Preston R.A., Jy W., Jimenez J.J., Mauro L.M., Horstman L.L., Valle M., et al. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension 41 (2003) 211-217
9. Lande K., Os I., Kjeldsen S.E., Westheim A., Hjermann I., Eide I., et al. Increased platelet size and release reaction in essential hypertension. J Hypertens 5 (1987) 401-406
10. Kamath S., Blann A.D., Caine G.J., Gurney D., Chin B.S., and Lip G.Y. Platelet P-selectin levels in relation to plasma soluble P-selectin and beta-thromboglobulin levels in atrial fibrillation. Stroke 33 (2002) 1237-1242
11. Masuda H. Vascular endothelial growth factor and platelets. Intern Med 39 (2000) 527-528
12. Webb N.J., Bottomley M.J., Watson C.J., and Brenchley P.E. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting. implications for measurement of circulating VEGF levels in clinical disease. Clin Sci 94 (1998) 395-404
13. Li J.J., Huang Y.Q., Basch R., and Karpatkin S. Thrombin induces the release of angiopoietin-1 from platelets. Thromb Haemost 85 (2001) 204-206
14. Ma L., Elliott S.N., Cirino G., Buret A., Ignarro L.J., and Wallace J.L. Platelets modulate gastric ulcer healing. role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci USA 98 (2001) 6470-6475
15. Shtivelband M.I., Juneja H.S., Lee S., and Wu K.K. Aspirin and salicylate inhibit colon cancer metastasis. J Thromb Haemost 1 (2003) 2225-2233
16. Belgore F.M., Blann A.D., Li-Saw-Hee F.L., Beevers D.G., and Lip G.Y. Plasma levels of vascular endothelial growth factor and its soluble receptor (sFlt-1) in essential hypertension. Am J Cardiol 87 (2001) 805-807 A9
17. le Noble F.A., Stassen F.R., Hacking W.J., and Struijker Boudier H.A. Angiogenesis and hypertension. J Hypertens 16 (1998) 1563-1572
18. Struijker Boudier H.A., le Noble J.L., Messing M.W., Huijberts M.S., le Noble F.A., and van Essen H. The microcirculation and hypertension. J Hypertens 10 Suppl (1992) S147-S156
19. Sullivan J.M., Prewitt R.L., and Josephs J.A. Attenuation of the microcirculation in young patients with high-output borderline hypertension. Hypertension 5 (1983) 844-851
20. Ramsay L., Williams B., Johnston G., MacGregor G., Poston L., Potter J., et al. Guidelines for management of hypertension. report of the third working party of the British Hypertension Society. J Hum Hypertens 13 (1999) 569-592
21. Blann A.D., Nadar S.K., and Lip G.Y. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 24 (2003) 2166-2179
22. Nadar S., Blann A.D., and Lip G.Y. Platelet morphology and plasma indices of platelet activation in essential hypertension. effects of amlodipine-based antihypertensive therapy. Ann Med 36 (2004) 552-557
23. Nadar S.K., Blann A.D., and Lip G.Y. Plasma and platelet-derived vascular endothelial growth factor and angiopoietin-1 in hypertension. effects of antihypertensive therapy. J Intern Med 256 (2004) 331-337
24. Nadar S.K., Blann A.D., Kamath S., Beevers D.G., and Lip G.Y. Platelet indexes in relation to target organ damage in high-risk hypertensive patients. a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Am Coll Cardiol 44 (2004) 415-422
25. Bath P.M., Carney C., Markandu N.D., and MacGregor G.A. Platelet volume is not increased in essential hypertension. J Hum Hypertens 8 (1994) 457-459
26. Maloney J.P., Silliman C.C., Ambruso D.R., Wang J., Tuder R.M., and Voelkel N.F. In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol 275 (1998) H1054-H1061
27. Salgado R., Benoy I., van Marck E., Vermeulen P., and Dirix L. The importance of the VEGF-load in platelets in cancer patients. Ann Oncol 13 (2002) 1689-1690
28. Chin B.S., Chung N.A., Gibbs C.R., Blann A.D., and Lip G.Y. Vascular endothelial growth factor and soluble P-selectin in acute and chronic congestive heart failure. Am J Cardiol 90 (2002) 1258-1260
29. Chung N.A., Lydakis C., Belgore F., Blann A.D., and Lip G.Y. Angiogenesis in myocardial infarction. An acute or chronic process?. Eur Heart J 23 (2002) 1604-1608
30. Makin A.J., Chung N.A., Silverman S.H., and Lip G.Y. Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease. a link between angiogenesis and thrombogenesis?. Clin Sci (Lond) 104 (2003) 397-404
31. Felmeden D.C., Spencer C.G., Chung N.A., Belgore F.M., Blann A.D., Beevers D.G., et al. Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT]). Am J Cardiol 92 (2003) 400-405
32. Dvorak H.F., Brown L.F., Detmar M., and Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyper-permeability, and angiogenesis. Am J Pathol 146 (1995) 1029-1039
33. Ferrara N., Winer J., and Burton T. Aortic smooth muscle cells express and secrete vascular endothelial growth factor. Growth Factors 5 (1991) 141-148
34. Leahy K.M., Koki A.T., and Masferrer J.L. Role of cyclooxygenases in angiogenesis. Curr Med Chem 7 (2000) 1163-1170
35. Sales K.J., Katz A.A., Howard B., Soeters R.P., Millar R.P., and Jabbour H.N. Cyclooxygenase-1 is up-regulated in cervical carcinomas. autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res 62 (2002) 424-432
36. Tamura M., Sebastian S., Gurates B., Yang S., Fang Z., and Bulun S.E. Vascular endothelial growth factor up-regulates cyclooxygenase-2 expression in human endothelial cells. J Clin Endocrinol Metab 87 (2002) 3504-3507
37. Sawaoka H., Tsuji S., Tsujii M., Gunawan E.S., Sasaki Y., Kawano S., et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 79 (1999) 1469-1477
38. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., and DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93 (1998) 705-716
39. Dermond O., and Ruegg C. Inhibition of tumor angiogenesis by non-steroidal anti-inflammatory drugs. emerging mechanisms and therapeutic perspectives. Drug Resist Update 4 (2001) 314-321
40. Rhee J.S., Black M., Schubert U., Fischer S., Morgenstern E., Hammes H.P., et al. The functional role of blood platelet components in angiogenesis. Thromb Haemost 92 (2004) 394-402
41. Gerrah R., Fogel M., and Gilon D. Aspirin decreases vascular endothelial growth factor release during myocardial ischaemia. Int J Cardiol 94 (2004) 25-29
42. Shtivelband M.I., Juneja H.S., Lee S., and Wu K.K. Aspirin and salicylate inhibit colon cancer me. J Thromb Haemost 1 (2003) 2225-2233
43. Pearce H.R., Kalia N., Bardhan K.D., and Brown N.J. Effects of aspirin and indomethacin on endothelial cell proliferation in vitro. J Gastroenterol Hepatol 18 (2003) 1180-1187
44. Blann A.D., Nadar S., and Lip G.Y. Pharmacological modulation of platelet function in hypertension. Hypertension 42 (2003) 1-7
45. Pernerstorfer T., Eichler H.G., Stohlawetz P., Speiser W., and Jilma B. Effects of heparin and aspirin on circulating P-selectin, E-selectin and von Willebrand factor levels in healthy men. Atherosclerosis 155 (2001) 389-393
46. Jilma B., Blann A., Pernerstorfer T., Stohlawetz P., Eichler H.G., Vondrovec B., et al. Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin. Am J Respir Crit Care Med 159 (1999) 857-863
47. Pernerstorfer T., Stohlawetz P., Stummvoll G., Kapiotis S., Szekeres T., Eichler H.G., et al. Low-dose aspirin does not lower in vivo platelet activation in healthy smokers. Br J Haematol 102 (1998) 1229-1231
48. van Pampus E.C., Huijgens P.C., Zevenbergen A., Twaalfhoven H., van Kamp G.J., and Langenhuijsen M.M. Influence of aspirin on human megakaryocyte prostaglandin synthesis. Eur J Haematol 50 (1993) 264-268
49. Gerrah R., Fogel M., and Gilon D. Aspirin decreases vascular endothelial growth factor release during myocardial ischemia. Int J Cardiol 94 (2004) 25-29